MY144492A - Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types - Google Patents

Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types

Info

Publication number
MY144492A
MY144492A MYPI20034868A MYPI20034868A MY144492A MY 144492 A MY144492 A MY 144492A MY PI20034868 A MYPI20034868 A MY PI20034868A MY PI20034868 A MYPI20034868 A MY PI20034868A MY 144492 A MY144492 A MY 144492A
Authority
MY
Malaysia
Prior art keywords
hpv
protection against
virus
particles
human papillomavirus
Prior art date
Application number
MYPI20034868A
Other languages
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef Mohamed Slaoui
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MY144492A publication Critical patent/MY144492A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI20034868A 2002-12-20 2003-12-18 Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types MY144492A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
MY144492A true MY144492A (en) 2011-09-30

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20034868A MY144492A (en) 2002-12-20 2003-12-18 Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types

Country Status (28)

Country Link
US (2) US20060251676A1 (cg-RX-API-DMAC7.html)
EP (1) EP1572233B1 (cg-RX-API-DMAC7.html)
JP (1) JP5475939B2 (cg-RX-API-DMAC7.html)
KR (3) KR101361769B1 (cg-RX-API-DMAC7.html)
AP (1) AP2005003347A0 (cg-RX-API-DMAC7.html)
AR (1) AR042530A1 (cg-RX-API-DMAC7.html)
AT (1) ATE503492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003293942B2 (cg-RX-API-DMAC7.html)
BE (3) BE2015C068I2 (cg-RX-API-DMAC7.html)
BR (1) BR0317544A (cg-RX-API-DMAC7.html)
CA (1) CA2510457C (cg-RX-API-DMAC7.html)
CY (1) CY1111552T1 (cg-RX-API-DMAC7.html)
DE (1) DE60336581D1 (cg-RX-API-DMAC7.html)
DK (1) DK1572233T3 (cg-RX-API-DMAC7.html)
EA (2) EA200701633A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055869A (cg-RX-API-DMAC7.html)
IL (1) IL169085A (cg-RX-API-DMAC7.html)
IS (1) IS2811B (cg-RX-API-DMAC7.html)
MA (1) MA27581A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006764A (cg-RX-API-DMAC7.html)
MY (1) MY144492A (cg-RX-API-DMAC7.html)
NO (1) NO20052846L (cg-RX-API-DMAC7.html)
NZ (1) NZ540811A (cg-RX-API-DMAC7.html)
OA (1) OA13147A (cg-RX-API-DMAC7.html)
PL (1) PL215257B1 (cg-RX-API-DMAC7.html)
PT (1) PT1572233E (cg-RX-API-DMAC7.html)
TW (1) TWI349557B (cg-RX-API-DMAC7.html)
WO (1) WO2004056389A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
AU2006239471A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
DK2154147T3 (en) * 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
WO2010099580A1 (en) * 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Treatment of infection
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
WO2015114506A2 (en) 2014-01-31 2015-08-06 Marini Bruna Biosensor for the determination of infections and associated pathologies
SG11201703262UA (en) 2014-10-24 2017-05-30 Hpvvax Llc Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
AU2016273638B2 (en) * 2015-06-02 2019-06-06 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
AU2019231652B2 (en) 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
EP3762022A4 (en) 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
US11771754B2 (en) * 2018-06-04 2023-10-03 Xiamen University Mutant of L1 protein of human papillomavirus type 18
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
DK1015561T3 (da) 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
ES2313881T3 (es) * 1999-02-05 2009-03-16 MERCK & CO., INC. Formulaciones de vacunas frente al papilomavirus humano.
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
EP1572233A1 (en) 2005-09-14
BE2015C067I2 (cg-RX-API-DMAC7.html) 2024-08-08
TWI349557B (en) 2011-10-01
MA27581A1 (fr) 2005-10-03
BE2015C069I2 (cg-RX-API-DMAC7.html) 2024-08-08
KR101361769B1 (ko) 2014-02-10
IL169085A0 (en) 2007-07-04
IS2811B (is) 2012-11-15
EA200500834A1 (ru) 2006-02-24
ECSP055869A (es) 2005-09-20
US20050287161A1 (en) 2005-12-29
OA13147A (en) 2006-12-13
NO20052846L (no) 2005-07-13
KR20120123616A (ko) 2012-11-08
DK1572233T3 (da) 2011-06-27
WO2004056389A1 (en) 2004-07-08
IL169085A (en) 2014-04-30
MXPA05006764A (es) 2005-09-08
KR20120118087A (ko) 2012-10-25
EP1572233B1 (en) 2011-03-30
NZ540811A (en) 2007-03-30
DE60336581D1 (de) 2011-05-12
KR20050086924A (ko) 2005-08-30
IS7885A (is) 2005-06-09
AP2005003347A0 (en) 2005-06-30
CA2510457A1 (en) 2004-07-08
JP2006512413A (ja) 2006-04-13
BR0317544A (pt) 2005-11-22
EA200701633A1 (ru) 2007-12-28
BE2015C068I2 (cg-RX-API-DMAC7.html) 2024-08-08
AU2003293942B2 (en) 2009-12-10
JP5475939B2 (ja) 2014-04-16
PL377710A1 (pl) 2006-02-06
PT1572233E (pt) 2011-06-07
EA009179B1 (ru) 2007-12-28
PL215257B1 (pl) 2013-11-29
ATE503492T1 (de) 2011-04-15
CA2510457C (en) 2011-12-06
AR042530A1 (es) 2005-06-22
HK1085378A1 (en) 2006-08-25
US20060251676A1 (en) 2006-11-09
AU2003293942A1 (en) 2004-07-14
CY1111552T1 (el) 2015-08-05
TW200423957A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
AP1872A (en) Virus-like particles of human papillomavirus.
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
IL202978A0 (en) West nile virus vaccine
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
FR15C0084I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
HUS1500059I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2005062739A3 (en) S-allylmercaptocysteine prodrugs and methods of treatment
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
UA85377C2 (ru) Применение композиции, содержащей вирусоподобные частички hpv16 і hpv18 при приготовлении медикамента для профилактики инфекции и/или болезни, вызванной группой hpv онкогенных типов, способы индуцирования иммунной реакции, профилактики инфекции и/или болезни, профилактики в популяции субъектов инфекции вызванных одной или несколькими группами онкогенных типов hpv, вакцинная композиция, которая включает hpv16 і нр18
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
MX2007013475A (es) Vacuna.
TW200716169A (en) Vaccine
WO2006069911A3 (en) Mucoadhesive pharmaceutical compositions comprising chemoattractants
UA67251A (en) Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums
UA67250A (en) Strain bovinae herpesvirus-1 "moldavian" for the preparation of vaccines and diagnosticums
MY146370A (en) Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same
HK1074847A (en) Infectious cdna of an approved vaccine strain of measles virus, use for immunogenic compositions